Shingrix Vaccination Rates Surge Among Newly Eligible Adults, but Disparities Persist
Event summary
- Truveta study found Shingrix vaccination rates rose to 14.0% among adults who turned 50 in 2024, up from 2.6% in 2018.
- 27.5% of adults who turned 50 in 2022 received the vaccine within three years of eligibility.
- 62.6% of those who initiated vaccination within a year of eligibility completed the two-dose series within six months.
- Disparities persist: Black adults, Medicaid/CHIP enrollees, rural residents, and individuals with cardiovascular disease were less likely to receive the vaccine.
The big picture
The study highlights a significant increase in Shingrix vaccination rates among newly eligible adults, reflecting growing acceptance of the vaccine. However, persistent disparities across racial, geographic, and socioeconomic groups underscore the need for targeted public health initiatives. Truveta's analysis, leveraging its extensive healthcare data network, provides critical insights for improving vaccination strategies and addressing healthcare inequities.
What we're watching
- Public Health Strategy
- How co-administration with influenza vaccines will affect Shingrix uptake rates.
- Healthcare Equity
- Whether targeted interventions can reduce disparities among Black adults, rural communities, and Medicaid enrollees.
- Vaccination Completion
- The pace at which completion rates of the two-dose series improve among underserved populations.
Related topics